The $Novavax (NVAX.US)$ news on imminent approvals from oth...
The $Novavax (NVAX.US)$ news on imminent approvals from other countries besides the ones already making the news, has sent a clear message... $Moderna (MRNA.US)$ rev/growth will definitely be disrupted and will have to be revised for 2022 and beyond. As Moderna management also stated this FACT.
That drop down to that $260 level needs filling in that huge gap on the way down..lol. More pain likely coming, as Moderna is still way overvalued.
Loving my little short position on Moderna, as more NVAX positive catalyst's arrive concerning more EUA/EUL approvals.
Cheers my friend.
Martini time !!
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Better than Youtuber : When people are so hyped about an approval from 3rd world country Which was denied by US, please be mindful that bad news could still be on the way. MRNA is still dominating the market.
Spider-Man to moon : "That drop down to that $260 level needs filling in that huge gap on the way down."
You've been saying this for how long now? It's still around the $325-350 range. Once it get its approval for kids by the FDA (early next year) it'll hop back up.
And meanwhile your "vaporware" is just that...VAPORWARE.
0 products on market
0 approval from 0 countries.
Just lots of "applications" and "submissions".
Gotta make a sale first so before talking the talk, you gotta walk the walk.
And Moderna not only WALKS the walk...they're running.....no correction SPRINTING away.
How's that watered down martini?
fly up high Spider-Man to moon : first of many NVAX approvals came today. Several more coming in the next month.
Spider-Man to moon fly up high : Agree Lobster. Have a nice lobster dinner on $NVAX Novavax. And enjoy the seaside sunset tonight.
madman123 Better than Youtuber : MRNA already priced in u dumbo... NVAX only just starting to price in..
Pcube : There's potential for NVAX as it is a different type of vaccine, price is different, impression of vaccine is different. Besides, vaccine is just a vaccine, 3rd world country population is far larger than developed world country population. First mover has advantage, so does late entrant, who can reduce the first mover market share.
Logan Harris : Nice sharing. Would love to read more of your review.